FDA Alert & HHS Antiretroviral Guidelines Panel: Regarding the Use of Dolutegravir in Adults and Adolescents With HIV Who Are Pregnant or of Child-Bearing Potential
The Food and Drug Administration (FDA) Drug Safety Communication and the Department of Health and Human Services (HHS) Antiretroviral Guidelines Panel issued the attached letter regarding the potential risk of the antiretroviral medication dolutegravir (DTG) associated with neural tube birth …